Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies

  • F. M. Watzka
  • F. Meyer
  • J. I. Staubitz
  • C. Fottner
  • A. Schad
  • H. Lang
  • T. J. MusholtEmail author
Original Scientific Report



In contrast to exocrine pancreatic carcinomas, prognosis and treatment of pancreatic neuroendocrine neoplasms (PNEN) are significantly different. The variable growth pattern and associated clinical situation of functioning and non-functioning PNEN demand an individualized surgical approach. However, due to the scarce evidence associated with the rare disease, guidelines lack detailed recommendations for indication and for the required extent of surgical resection.


In a retrospective single-center study from 1990 to 2018, 239 patients with PNEN were identified. Clinical data were collected in the MaDoc database of the University Medical Center Mainz. A total of 155 non-functional PNEN were selected for further analysis.


According to the classification of NET by the WHO in 2017, 28.8% (n = 40) of the tumors were G1, 61.9% (n = 86) G2, and 9.4% (n = 13) G3. In 73 patients, hepatic metastases were present. Sixty patients had lymph node metastasis. An R0 resection was achieved in 98 cases, an R1 situation in 10 cases. Five times, a tumor debulking was carried out (R2) and 5 times the operation was aborted without any resection because of the advanced tumor stage. A relapse occurred in 29 patients. Different prognostic factors (grade, tumor size, age) were analyzed. Grade-dependent 10-year overall survival rates were 79.5% (grade 1) and 60.1% (grade 2), respectively. The survival rate of grade 3 patients was limited to 66.7% after 13 months.


In our study, patients with non-functioning PNEN had a longer overall survival after successful R0 resection. The risk analysis confirmed a Ki-67 cutoff value of 5%, which divided a high- and low-risk group. Patients with a PNEC G3 (Ki-67 index > 50%) had a very poor prognosis.


Compliance with ethical standards

Conflicts of interest

No potential conflicts of interest to be announced.


  1. 1.
    Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRefGoogle Scholar
  2. 2.
    Kimura W, Kuroda A, Morioka Y (1991) Clinical pathology of endocrine tumors of the pancreas. Anal Autops Cases Dig Dis Sci 36:933–942CrossRefGoogle Scholar
  3. 3.
    Ito T, Igarashi H, Nakamura K et al (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 50:58–64CrossRefGoogle Scholar
  4. 4.
    Hallet J, Law CH, Cukier M et al (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation and outcomes. Cancer 121:589–597CrossRefGoogle Scholar
  5. 5.
    Frilling A, Modlin IM, Kidd M et al (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15:e8–21CrossRefGoogle Scholar
  6. 6.
    Fesinmeyer MD, Austin MA, Li CI et al (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev 14:1766–1773CrossRefGoogle Scholar
  7. 7.
    Gratian L, Pura J, Dinan M et al (2014) Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. Ann Surg Oncol 21:3515–3521CrossRefGoogle Scholar
  8. 8.
    Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103:153–171CrossRefGoogle Scholar
  9. 9.
    Rinke A, Wiedenmann B, Auernhammer C et al (2018) Practice guideline neuroendocrine tumors—AWMF-Reg. 021-27. Z Gastroenterol 56:583–681CrossRefGoogle Scholar
  10. 10.
    Kulke MH, Shah MH, Benson AB 3rd et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw JNCCN 13:78–108CrossRefGoogle Scholar
  11. 11.
    Ferrone CR, Tang LH, Tomlinson J et al (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25:5609–5615CrossRefGoogle Scholar
  12. 12.
    Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRefGoogle Scholar
  13. 13.
    Liszka L (2016) Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas. Pol J Pathol 67:318–331CrossRefGoogle Scholar
  14. 14.
    Hauck L, Bitzer M, Malek N et al (2016) Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors. Scand J Gastroenterol 51:55–59CrossRefGoogle Scholar
  15. 15.
    Genc CG, Jilesen AP, Partelli S et al (2018) A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg 267:1148–1154CrossRefGoogle Scholar
  16. 16.
    Panzuto F, Boninsegna L, Fazio N et al (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29:2372–2377CrossRefGoogle Scholar
  17. 17.
    Partelli S, Maurizi A, Tamburrino D et al (2014) Surgical management of pancreatic neuroendocrine neoplasms. Ann Saudi Med 34:1–5CrossRefGoogle Scholar
  18. 18.
    D’Haese JG, Tosolini C, Ceyhan GO et al (2014) Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol 20:13893–13898CrossRefGoogle Scholar
  19. 19.
    Radu EC, Saizu AI, Grigorescu RR et al (2018) Metastatic neuroendocrine pancreatic tumor—case report. J Med Life 11:57–61PubMedPubMedCentralGoogle Scholar
  20. 20.
    Halfdanarson TR, Rabe KG, Rubin J et al (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733CrossRefGoogle Scholar
  21. 21.
    Watzka FM, Fottner C, Miederer M et al (2015) Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. Langenbecks Arch Surg 400:349–358CrossRefGoogle Scholar
  22. 22.
    Shatveryan GA, Karagyozyan GA, Chardarov NK et al (2018) Surgical management of non-functioning pancreatic neuroendocrine tumors. Khirurgiia (Mosk). CrossRefGoogle Scholar
  23. 23.
    Ricci C, Casadei R, Taffurelli G et al (2016) Validation of the 2010 WHO classification and a new prognostic proposal: a single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. Pancreatology 16:403–410CrossRefGoogle Scholar
  24. 24.
    Scarpa A, Mantovani W, Capelli P et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23:824–833CrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2019

Authors and Affiliations

  • F. M. Watzka
    • 1
  • F. Meyer
    • 1
  • J. I. Staubitz
    • 1
  • C. Fottner
    • 2
  • A. Schad
    • 3
  • H. Lang
    • 3
  • T. J. Musholt
    • 1
    Email author
  1. 1.Endocrine Surgery, Clinic of General, Visceral- and Transplantation SurgeryUniversity Medical Center University MainzMainzGermany
  2. 2.Endocrinology and Metabolic DiseasesUniversity Medical Center University MainzMainzGermany
  3. 3.Institute of PathologyUniversity Medical Center University MainzMainzGermany

Personalised recommendations